Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shenzhen Rhegen Biotechnology Co. Ltd. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active for this portfolio. This action is assigned to 1 distinct examiner working within the specified art unit. This structure indicates that the company's current legal efforts in the Biotechnology & Pharmaceuticals sector are focused on a single point of examination.
KELLY, ROBERT M is the busiest examiner for this portfolio and is responsible for the busiest examiner pending action. Because the total count of pending office actions matches this examiner's workload, this individual is managing the entirety of the company's current applications. The concentration in the distinct art unit means that the prosecution is not spread across different specialized groups within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18329015 | Mannose-Based mRNA Targeted Delivery System and Use Thereof | KELLY, ROBERT M | 28d |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18329015 | Mannose-Based mRNA Targeted Delivery System and Use Thereof | KELLY, ROBERT M | 1638 | §112DP | Final Rejection | 28d | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial